OncoMatch/Clinical Trials/NCT06066346
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Is NCT06066346 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Talquetamab for multiple myeloma.
Treatment: Talquetamab — The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immunomodulatory agent
prior treatment with an IMID
Must have received: proteasome inhibitor
prior treatment with a PI
Must have received: CD38-targeted therapy
prior treatment with a CD38 monoclonal antibody
Must have received: BCMA CAR-T cell therapy (ide-cel)
Received treatment with an FDA approved BCMA CART cell therapy ide-cel within 1-3 months prior to enrollment
Cannot have received: GPRC5D-directed therapy
Received any prior GRPRC5D-directed therapy
Cannot have received: T-cell redirection therapy
Exception: within 3 months
T-cell redirection therapy (for example, antibody therapy or BiTE's) within 3 months
Cannot have received: investigational vaccine
Exception: other than SARS CoV-2 vaccine approved/ in use under emergency approval within 4 weeks
Investigational vaccine other than SARS CoV-2 vaccine approved/ in use under emergency approval within 4 weeks
Cannot have received: live, attenuated vaccine
Exception: within 4 weeks
Live, attenuated vaccine within 4 weeks
Cannot have received: monoclonal antibody therapy
Exception: within 21 days (with the exception of COVID monoclonal antibodies)
Monoclonal antibody therapy within 21 days (with the exception of COVID monoclonal antibodies)
Cannot have received: cytotoxic chemotherapy
Exception: within 21 days
Cytotoxic therapy within 21 days
Cannot have received: proteasome inhibitor
Exception: within 14 days
PI therapy within 14 days
Cannot have received: immunomodulatory agent
Exception: within 14 days
IMiD agent therapy within 14 days
Cannot have received: radiation therapy
Exception: within 14 days or focal radiation within 7 days
Radiotherapy within 14 days or focal radiation within 7 days
Cannot have received: major surgery
Exception: within 14 days
Major surgery (as defined by the investigator) within 14 days
Cannot have received: plasmapheresis
Exception: within 14 days
Plasmapheresis within 14 days
Cannot have received: allogeneic stem cell transplant
Exception: within 6 months before the first dose of study treatment
An allogeneic SCT within 6 months before the first dose of study treatment
Cannot have received: autologous stem cell transplant
Exception: within 12 weeks before the start of study treatment administration
An autologous SCT within 12 weeks before the start of study treatment administration
Lab requirements
Blood counts
ANC ≥ 1,000/mm^3 (no growth factor support for 7-14 days); Platelets ≥ 75,000/mm^3 (no transfusion/thrombopoietin receptor agonist in previous 7 days); Platelets ≥ 50,000/mm^3 if pre-lymphodepletion <75,000; Hemoglobin ≥ 8 g/dL (no transfusion/erythropoietin within 7 days)
Kidney function
CrCl/eGFR ≥ 30 mL/min, measured by 24 hour urine or CKD-EPI2021
Liver function
AST and ALT ≤ 2.5 x ULN; total bilirubin ≤ 2 x ULN (except Gilbert syndrome: direct bilirubin ≤1.5 x ULN)
Cardiac function
LVEF ≥ 45% by ECHO or MUGA
Absolute neutrophil count (ANC) ≥ 1,000/mm^3 ... Platelet count ≥ 75,000/mm^3 ... Hemoglobin ≥ 8 g/dL ... Creatinine Clearance (CrCl)/eGFR ≥ 30 mL/min ... AST and ALT ≤ 2.5 x ULN ... total bilirubin ≤ 2 x ULN ... LVEF ≥ 45% by ECHO or MUGA
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify